Scarica l'app Stockscreener
1.94
4.43%
-0.09
Dopo l'orario di chiusura:
1.94
Century Therapeutics Inc Borsa (IPSC) Ultime notizie
Century Therapeutics (IPSC) awards 148,000 options vesting over 3 years - Stock Titan
Century Therapeutics' SVP Finance Carr Douglas Sells 254 Shares at $2.05 Each (NASDAQ: IPSC) - Kalkine Media
Century Therapeutics SVP sells $520 in stock for tax withholding By Investing.com - Investing.com Australia
Century Therapeutics appoints iECURE CEO Joseph Truitt to board - Bitget
Century Therapeutics Adds Joseph Truitt to Board of Directors - Minichart
Century Therapeutics CEO Brent Pfeiffenberger Withholds Shares for Tax on RSU Vesting - Kalkine Media
Century Therapeutics CTO Gregory Russotti Executes Automatic Sale of 534 Shares for Tax Withholding - Kalkine Media
Century Therapeutics SVP sells $520 in stock for tax withholding - Investing.com
Century Therapeutics Adds Director, Advances Cell Therapy Pipeline - TipRanks
Century Therapeutics (IPSC) CEO shares withheld for taxes on RSU vesting - Stock Titan
Tax-withholding sale trims Century Therapeutics (NASDAQ: IPSC) insider by 534 shares - Stock Titan
Automatic tax sale leaves Century Therapeutics (NASDAQ: IPSC) SVP with 504,565 shares - Stock Titan
Century Therapeutics appoints Joseph Truitt to board By Investing.com - Investing.com India
Century Therapeutics adds director, sets 2026 trial timelines - Stock Titan
Century Therapeutics Appoints Joseph Truitt to Board of Directors - Yahoo Finance UK
Century Therapeutics (NASDAQ: IPSC) officer plans stock sale partly to cover taxes - Stock Titan
Century (IPSC) Earnings Reading: EPS Beats Its Estimate at the Close; Share Move: The Stock Records a 4.27% Decrease in Latest TradingGuidance vs Actual - vinanet.vn
Century Targets FDA Filing for Diabetes Cell Therapy - MyChesCo
Century Therapeutics CEO Brent Pfeiffenberger Completes RSU Tax Withholding Share Transaction - Kalkine Media
Century Therapeutics (IPSC) CEO stock withheld for taxes - Stock Titan
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
HC Wainwright Issues Pessimistic Forecast for IPSC Earnings - MarketBeat
IPSC Q1 2026 Earnings: Narrower-Than-Expected Loss Yields 31.76% EPS SurpriseMid-Term Outlook - vinanet.vn
TD Cowen Maintains Century Therapeutics(IPSC.US) With Buy Rating - Moomoo
Century Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Century Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Century Therapeutics (NASDAQ:IPSC) Issues Quarterly Earnings Results - MarketBeat
Century Therapeutics Announces Q2 2026 Financial Results and Updates Investor Presentation in 8-K Filing - Kalkine Media
Form 8K Century Therapeutics Inc For: 12 August - Investing.com India
Century Therapeutics Reports Q2 Results, Pipeline Advancements - TipRanks
Form 8K Century Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Century Therapeutics posts $34.6 million Q2 loss as cash runway reaches 2029 - Quiver Quantitative
Century Therapeutics 2Q 2026: Revenue $0 EPS $(0.17) — 10-Q Summary - TradingView
Century Therapeutics Q2 net loss misses estimates on lease termination loss - TradingView
Century Therapeutics (IPSC) books $34.6M loss but holds $197M cash - Stock Titan
We Think Century Therapeutics (NASDAQ:IPSC) Needs To Drive Business Growth Carefully - Moomoo
Century Therapeutics (IPSC) Projected to Announce Earnings on Thursday - MarketBeat
Century Therapeutics (IPSC) SVP has automatic share sale to cover RSU taxes - Stock Titan
Seven Fleet Capital Management LP Takes Position in Century Therapeutics, Inc. $IPSC - MarketBeat
DV Trading LLC Makes New Investment in Century Therapeutics, Inc. $IPSC - MarketBeat
Century Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Century Therapeutics Inc (IPSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Century Therapeutics Inc (IPSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Commodore Capital LP Purchases New Position in Century Therapeutics, Inc. $IPSC - MarketBeat
Century Therapeutics Inc (IPSC) Cash Flow - TradingKey
IPSC|Century Therapeutics Inc|Price:2.110|Chg%:-0.060 - TradingKey
Century Therapeutics Inc (IPSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Century Therapeutics Inc (IPSC) Institutional Confidence - TradingKey
Century Therapeutics, Inc. Revenue Breakdown – NASDAQ:IPSC - TradingView
Spruce Street Capital LP Acquires 2,637,522 Shares of Century Therapeutics, Inc. $IPSC - MarketBeat
Century Therapeutics Q1 2026 Earnings: Narrower Loss Than Expected, But Stock FadesEPS Surprise History - vinanet.vn
IPSC stock trades steadily as Century Therapeutics updates its pipeline and cash runway - Ad-hoc-news.de
IPSC stock trades around recent lows as Century Therapeutics weighs pipeline and cash burn - Ad-hoc-news.de
Century Therapeutics (IPSC) Posts Modest Gain as Stock Holds Above Key Support LevelHigh Yield Stocks - vinanet.vn
Century Therapeutics (IPSC) Dips 2.7% as Shares Near Key Support ZoneDividend Stock Picks - dars.gov.et
Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses - Yahoo Finance
Century: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative Potential - Seeking Alpha
Century Therapeutics abstracts accepted for diabetes conferences - Investing.com
Century Therapeutics abstracts accepted for diabetes conferences By Investing.com - Investing.com South Africa
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026 - Investing News Network
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):